PureTech Health plc PRTCY
Set alert
15.31 USD -0.40 -2.55%
As of Nov 2, 12:00 PM ET
15.31 Day range 15.31
13.93 52-week range 19.92
- YTD
- -7.99%
- 1 year
- -13.84%
- Open
- 15.31
- Prev close
- 15.71
- Mkt cap
- 375.37M
- Vol
- 50
- Avg vol
- 2.41K
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 15.31
- High
- 15.31
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 3 hours ago |
| SMA: Bullish | Oct 30, 2026 | 3 days ago |
| SMA: Bearish | Oct 29, 2026 | 4 days ago |
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 26, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
Financials — quick view
PRTCY Revenue — annual 4.66M
PRTCY Net income — annual -109.74M
PRTCY EPS — annual -4.60
News
- PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category
- PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
- PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
- PureTech Health plc (PRTCY) Q2 2026 Earnings Call Transcript
- PureTech Health H1 Earnings Call Highlights
- PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
- PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
Your note
Sign in to keep a note on PRTCY — it syncs with the Stock Master app.